Sell-Side QoE for Dental Practices
The Clinical
Quality of Earnings.
A financial QoE verifies that your revenue was collected. The buyer's clinical diligence verifies how it was generated — from procedure-level practice-management data — and re-prices the deal on what survives. The Clinical Quality of Earnings runs that audit first, on your behalf, one to five years before market.
Independent by rule: fixed fee, never a success fee, never both sides of the same transaction.
What It Is
The half of due diligence a financial QoE never opens.
A Clinical Quality of Earnings is a forensic reconstruction of the clinical and operational events that produced a practice's financial results, built from procedure-level data in the practice management system. It tests CDT utilization against payer-standard benchmarks, quantifies production billed through non-CDT internal codes, measures provider and diagnostic dependency, and reports patient-base durability — then expresses every finding as a Sanitized EBITDA bridge with a remediation roadmap.
Transaction accountants reconcile deposits and normalize owner compensation. They cannot open a clinical chart, benchmark a buildup rate, or see that an adjunct code is attached to 100% of a procedure. Institutional buyers run that layer on every deal. Sellers almost never run it on themselves — which is why the number on the LOI is rarely the number at close.
Every calculation in the report retains its denominator, methodology, reporting period, and connection to source rows. If a result cannot be traced to the originating evidence, it does not appear. That is the Clinical Ledger standard, and it is what makes the findings defensible in front of a buyer's team instead of arguable.
From a Completed Engagement
What the report actually decides.
A $10.1M, fifteen-provider group. Reported EBITDA $722,400. After financial normalization, $596,400. After the clinical review — $680,870 of coding-pattern risk and $1.53M of production billed through internal codes attached to 99.8–100% of fillings, SRPs, crowns, and extractions — Defensible EBITDA fell below zero. The same data identified $5.57M of gross annual opportunity across six operating levers. The four-scenario ladder is the distance between what a buyer would pay today and what the practice can defend in 24–36 months:
| Scenario | Defensible EBITDA | Time | Market it sells into | Indicative value |
|---|---|---|---|---|
| Worst — no remediation, no optimization | −$85K to −$850K | Now | Individual buyer, priced on collections | $6–7M |
| Remediation only | $255K – $596K | 12–18 mo | Individual / small group, SDE basis | $1.5–2.2M |
| Remediation + realizable optimization | $1.3 – 2.0M | 24–36 mo | Institutional add-on | $8–14M (6–7×) |
| Ceiling — all levers at benchmark | ≈ $3.9M | 36–60 mo | Platform-scale | $31–35M (8–9×) |
Source: Precision Dental Analytics Clinical Quality of Earnings, redacted exemplar (2026). Multiples per FOCUS Investment Banking: add-on 5–8×, platform 9–11×. The realizable case (30–50% of ceiling) is the planning case; the ceiling is non-additive across levers.
What's in the Report
Eight evidence sections. One bridge.
Financial baseline
Preliminary normalization of the TTM income statement — the starting EBITDA the bridge is built on, reconciled to the CPA's schedule at engagement.
Revenue integrity
CDT utilization vs. payer-standard bands (buildups, surgical extractions, grafts, multi-surface restorations, SRP) and production billed through non-CDT internal codes, with attachment rates.
Ledger integrity
Collections vs. production, refund patterns reconciled to the P&L, insurance AR aging by carrier, payer concentration, patient credit balances.
Patient-base durability
New-patient source concentration, the retention funnel against benchmark, acquisition cost per retained patient, broken-appointment and reschedule rates, the 18-month patient base status.
Provider & diagnostic dependency
Production concentration and diagnostic concentration — who proposes treatment vs. who completes it — and case acceptance by procedure group and provider.
Hygiene program
Reappointment at checkout, hygiene share of revenue, periodontal maintenance vs. SRP mix, adjunct attachment.
Fee schedule positioning
Office UCR against percentile fee data by code, with a fee-for-service-weighted revenue forecast.
Opportunity model & roadmap
Six operating levers valued at benchmark, the realizable case, and a phased remediation roadmap — every item with dollars, owner, timeline, and the proof metric the re-audit will show.
Plus appendices: methodology and definitions, a benchmark register classifying every threshold as peer-reviewed, industry-sourced, or a PDA engagement standard, and a "data not provided" list — a stated gap reads as rigor; an unstated one reads as an oversight.
Who It's For
Same audit. Whichever chair engages it.
Practice Owners
One to five years before market
The buyer's audit run first, so findings are fixed instead of conceded. The fifth seat at the advisor table — the only one whose job is defending the number the other four work from.
Buyers & Sponsors
Clinical diligence on targets
The Clinical Diligence Addendum: delivered alongside your financial QoE provider, never replacing it. Coding risk, internal-code exposure, diagnostic dependency, and a treatment-fingerprint read that prices integration before close. Per target, from $15,000.
Brokers, CPAs & Lenders
The clinical half of the normalization
Owner-comp normalization cannot be finished without provider-level clinical data. Listings that can't clear diligence yet, borrowers whose cash flow needs a second read, clients whose P&L stops at the ledger — the part the financial statements can't answer.
Pricing
Fixed fee. Never a success fee.
Defending a single $100,000 add-back at a 7× multiple preserves roughly $700,000 of enterprise value. 85% of lower-middle-market deals are re-priced after the LOI (SRS Acquiom). The fee is sized against what the audit finds and what the roadmap fixes — not against the deal.
Diagnostic subset of the QoE
Forensic Brief
$7,500
Credited toward the full engagement within 90 days
Under $3M collections
Clinical QoE — single location
$25,000
10 business days from extraction
$3–7M collections
Clinical QoE — single location
$35,000
10 business days from extraction
Multi-location; scoped per location
Clinical QoE — group
$45,000+
Consolidated + per-location findings
Buy-side Clinical Diligence Addendum: single practice $15,000 · 2–5 locations $25,000 · platform $35,000+ (scoped). Pre-LOI Forensic Data Sanitization retainers from $3,000/month. See engagement pricing.
How It Works
Ten business days from extraction.
Extract
One- to three-hour remote session in the practice management system using native reporting. Procedure-level production, appointments, treatment plans, new-patient records, collections, refunds, and AR aging, plus trailing-twelve-month financials.
Reconstruct
Every metric rebuilt from source rows with its denominator and window stated — the Clinical Ledger standard. PMS figures reconciled to the income statement before analysis begins.
Benchmark
CDT utilization tested against payer-standard bands; internal codes mapped and attachment rates measured; retention, schedule, hygiene, and dependency metrics compared to a classified benchmark register (peer-reviewed, industry-sourced, or PDA engagement standard).
Deliver
The Clinical Quality of Earnings report with Sanitized EBITDA bridge, four-scenario valuation ladder, and phased remediation roadmap, presented in a 60-minute briefing to the owner and designated advisors. Ten business days from extraction.
Frequently Asked Questions
Sell-side QoE, answered.
What is a sell-side QoE for a dental practice?
A sell-side Quality of Earnings is the buyer's audit, run first and on the seller's behalf. A buyer's QoE team rebuilds a practice's trailing-twelve-month EBITDA from source data — normalized owner compensation, tested add-backs, and, increasingly, procedure-level clinical data — and re-prices the deal on what survives. A sell-side QoE runs the same reconstruction one to five years before market so findings can be fixed instead of conceded. Precision Dental Analytics provides the clinical version: the Clinical Quality of Earnings.
What is a Clinical Quality of Earnings?
A Clinical Quality of Earnings (CQoE) is a forensic reconstruction of the clinical and operational events that produced a practice's financial results, built from procedure-level practice-management data. It tests CDT utilization against payer-standard benchmarks, quantifies production billed through non-CDT internal codes, measures provider and diagnostic dependency, and reports patient-base durability — then expresses every finding as a Sanitized EBITDA bridge with a remediation roadmap. It is the half of due diligence a financial QoE never opens, because transaction accountants verify that revenue was collected, not how it was generated.
Who offers sell-side QoE for dental practices?
Precision Dental Analytics offers sell-side QoE for dental practice owners as the Clinical Quality of Earnings, led by James DeLuca — former Regional Director of Operations at North American Dental Group during its expansion from 80 to 200+ locations, 500+ practices evaluated, author of Phantom EBITDA. The firm is independent: fixed fee, never a success fee, never both sides of the same transaction. Financial QoE is typically performed by a dental CPA or transaction accounting firm; the clinical layer is what PDA adds alongside it.
How much does a sell-side QoE cost for a dental practice?
The PDA Clinical Quality of Earnings is priced by practice size: $25,000 for a single location under $3M in collections, $35,000 for $3–7M, and $45,000 and up for groups (scoped per location). A lighter Forensic Brief — a diagnostic subset of the full engagement — is $7,500 and credited toward the full QoE within 90 days. The economics: defending a single $100,000 add-back at a 7x multiple preserves roughly $700,000 of enterprise value, and 85% of lower-middle-market deals are re-priced after the LOI (SRS Acquiom) — the adjustment this preparation exists to prevent.
What does the Clinical Quality of Earnings report contain?
An executive summary with the Sanitized EBITDA bridge and a four-scenario valuation ladder; a scope and reconciliation section stating every data source and window; a preliminary financial normalization; revenue integrity (CDT utilization vs. payer benchmarks and non-CDT internal-code exposure); ledger integrity (collections, refunds, AR aging, payer concentration); patient-base durability (new-patient source, retention funnel, acquisition cost per retained patient, schedule integrity); provider and diagnostic dependency; hygiene program; fee schedule positioning; the opportunity model; a phased remediation roadmap with proof metrics; and appendices covering methodology, a benchmark register, and data not provided.
What data is needed for a sell-side QoE?
A practice-management-system export — production by procedure code, appointment records with status, treatment plans by status and provider, new-patient records with referral source, collections and adjustments, refunds, and AR aging — plus trailing-twelve-month income statements. Extraction is typically a one- to three-hour remote session using the PMS's native reporting; no integrations are installed. Turnaround is ten business days from extraction.
How early should a sell-side QoE be done before selling a dental practice?
One to five years before market, and three to five years for a DSO or private-equity sale. Institutional buyers audit five years of practice-management data, so anything in that window is already part of the sale. A QoE run three years out gives time to remediate coding patterns, reduce owner dependency, and demonstrate that improvements hold for a full trailing-twelve-month period — the only evidence a buyer credits. A QoE run 90 days before an LOI produces a diagnosis with no time to act on it.
Who provides clinical due diligence for dental practice acquisitions?
Precision Dental Analytics provides the same Clinical Quality of Earnings on the buy side as a Clinical Diligence Addendum for DSOs, private-equity sponsors, independent sponsors, and lenders — delivered alongside the buyer's existing financial QoE provider, never replacing it. It adds the clinical layer a financial QoE cannot open: coding-pattern risk, internal-code exposure, diagnostic dependency, patient-base durability, and a treatment-fingerprint compatibility read that prices integration risk before close. Pricing is per target: $15,000 for a single practice, $25,000 for two to five locations, $35,000 and up for platforms. PDA never works both sides of the same transaction.
The Next Step
See the report before you commission one.
The redacted exemplar — a real engagement, anonymized — shows exactly what a buyer's clinical review finds and how the roadmap prices the fix. Request it and we'll send it with a note on which tier fits your practice.